Xilio Therapeutics, Inc. 8K

Xilio Therapeutics filed a Form 8-K to report Q2 2026 results, FDA IND clearance for XTX501, progress on its masked T cell engager programs, a new chief legal officer, and a cash runway extending into Q1 2028.

Xilio Therapeutics, Inc. reported its second quarter 2026 financial results and provided business and pipeline updates, highlighted by FDA clearance of its IND application for XTX501, a bispecific PD-1 / masked IL-2 candidate, plans to initiate a Phase 1/2 trial in metastatic NSCLC and select advanced solid tumors in the second half of 2026, continued IND-enabling work on first-in-class multi-specific masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1 with planned IND filings in the second half of 2027, ongoing Phase 2 development of efarindodekin alfa with an option data package for Gilead expected in the first half of 2027, appointment of a new chief legal officer, and confirmation that its $136.0 million in cash and cash equivalents as of June 30, 2026 is expected to fund operations into the first quarter of 2028, excluding potential warrant exercises and milestone or option payments from AbbVie and Gilead.

Filing Facts

CIK

1840233

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-345753

Alert Tier

6